C1955832||Systematic Review
C0666743||Infliximab
C1122087||Adalimumab
C0085421||Drug Monitoring
C2985631||Clinical Outcomes
C1510438||Assays
C4054739||Immunogenicity
C1562242||anti-tumor necrosis factor-alpha agents
C0085421||Drug monitoring
C0031831||physicians
C1519193||scheme
C0237401||individually
C1706852||article
C1955832||systematically review
C0993637||published data
C0666743||infliximab
C0666743||infliximab
C1122087||adalimumab
C1122087||adalimumab
C0666743||infliximab
C1122087||adalimumab
C2985631||clinical outcomes
C1138432||PubMed database
C0020792||identify
C2603343||studies
C0205103||between
C0666743||infliximab
C1122087||adalimumab
C2985631||clinical outcomes
C0021390||inflammatory bowel disease
C1706852||articles
C1522634||queries
C0936012||analysis
C0020792||identify
C0666743||infliximab
C1122087||adalimumab
C2985631||clinical outcome
C2603343||studies
C0936012||analysis
C3811629||antidrug antibody
C0205103||between
C2603343||studies
C2985631||clinical outcomes
C1261153||measurement of drug levels
C0006560||C-reactive protein
C0026724||mucosal
C0221198||lesions
C0150312||present
C0013227||drug
C0005515||antidrug
C2985631||clinical outcomes
C0013227||drug
C1283169||monitoring
C3811629||antidrug antibody
C0025663||method